{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:31:56Z","timestamp":1787056316320,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"S&T Program of HeBei","award":["No.22377715D"],"award-info":[{"award-number":["No.22377715D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the pathogen distribution and risk factors for pulmonary infection (PI) in patients with advanced non- small cell lung cancer (NSCLC) treated with chemotherapy combined with immune checkpoint inhibitors (ICIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with advanced NSCLC who met the inclusion criteria were collected and divided into three groups: chemotherapy with PI group, chemotherapy combined with ICIs with PI group and chemotherapy combined with ICIs without PI group. We displayed the pathogen distribution and infection time of PI for different groups, and explored the risk factors for PI in chemotherapy combined with ICIs group of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 239 patients were included in the study, among which there were 30 cases in the chemotherapy with PI group, 68 cases in the chemotherapy combined with ICIs with PI group, and 141 cases in the chemotherapy combined with ICIs without PI group. The results revealed an increased bacterial infection rate of patients in the chemotherapy with PI group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Data analysis of patients with combined fungal infections showed a statistically significant difference in the incidence of fungal infections between the two groups (Fisher\u2019s exact test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035). Multivariate logistic regression analysis revealed that low lymphocyte (LYM) counts (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.016) and stage IV disease (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012) were independent risk factors for patients in the chemotherapy combined with ICIs with PI group, and number of immunotherapy cycles\u2009\u2265\u20095 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.031) was associated with a reduced likelihood of PI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this observational study, bacterial infections were more common with chemotherapy alone, whereas fungal infections predominated in patients receiving chemotherapy plus ICIs. Low lymphocyte count and stage IV disease were associated with higher pulmonary infection risk, while\u2009\u2265\u20095 cycles of immunotherapy was associated with lower risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13834-1","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:05:05Z","timestamp":1782378305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathogen distribution characteristics and risk factors of pulmonary infection associated with immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer: a case control study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ruixin","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6236-8476","authenticated-orcid":false,"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"6","key":"13834_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1055\/s-0042-1757885","volume":"43","author":"E Lee","year":"2022","unstructured":"Lee E, Kazerooni EA. Lung Cancer Screening. Semin Respir Crit Care Med. 2022;43(6):839\u201350.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"13834_CR2","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"13834_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","volume":"11","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: Progress, Challenges, and Prospects. Cells. 2022;11(3):320.","journal-title":"Cells"},{"issue":"21","key":"13834_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"key":"13834_CR5","doi-asserted-by":"publisher","first-page":"1266850","DOI":"10.3389\/fimmu.2024.1266850","volume":"15","author":"MX Lin","year":"2024","unstructured":"Lin MX, Zang D, Liu CG, et al. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. Front Immunol. 2024;15:1266850. Published. 2024 Feb 15.","journal-title":"Front Immunol"},{"issue":"2","key":"13834_CR6","doi-asserted-by":"publisher","first-page":"e170503","DOI":"10.1172\/JCI170503","volume":"134","author":"MI Ghanbar","year":"2024","unstructured":"Ghanbar MI, Suresh K. Pulmonary toxicity of immune checkpoint immunotherapy. J Clin Invest. 2024;134(2):e170503.","journal-title":"J Clin Invest"},{"issue":"Pt 2","key":"13834_CR7","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"13834_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709\u201317.","journal-title":"J Clin Oncol"},{"key":"13834_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","volume":"125","author":"JY Cho","year":"2018","unstructured":"Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor- related pneumonitis in patients with non- small cell lung cancer. Lung Cancer. 2018;125:150\u20136.","journal-title":"Lung Cancer"},{"issue":"2","key":"13834_CR10","first-page":"134","volume":"61","author":"Medical Mycology Society of Chinese Medicine and Education Association","year":"2022","unstructured":"Medical Mycology Society of Chinese Medicine and Education Association. Expert consensus on clinical application of laboratory diagnostic methods for invasive mycosis. Zhonghua nei ke za zhi. 2022;61(2):134\u201341. Chinese.","journal-title":"Zhonghua nei ke za zhi"},{"issue":"3","key":"13834_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","volume":"159","author":"T Johkoh","year":"2021","unstructured":"Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest. 2021;159(3):1107\u201325.","journal-title":"Chest"},{"issue":"7","key":"13834_CR12","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1148\/rg.2019190036","volume":"39","author":"KR Kalisz","year":"2019","unstructured":"Kalisz KR, Ramaiya NH, Laukamp KR, et al. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. Radiographics. 2019;39(7):1923\u201337.","journal-title":"Radiographics"},{"issue":"36","key":"13834_CR13","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"2","key":"13834_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw694","volume":"64","author":"DM Lewinsohn","year":"2017","unstructured":"Lewinsohn DM, Leonard MK, LoBue PA, et al. Official merican Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):e1\u201333.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"13834_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"13834_CR16","unstructured":"China association of medical equipment of genetic testing. Guidelines for standardized application of metagenomic high-throughput sequencing in clinical laboratories (2026 edition) [J]. Chin Med J. 2026;106(14):1304\u201317."},{"issue":"20","key":"13834_CR17","first-page":"1790","volume":"104","author":"Chinese Society Dermatology of the Chinese Medical Association","year":"2024","unstructured":"Chinese Society Dermatology of the Chinese Medical Association. Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition). Zhonghua Yi Xue Za Zhi. 2024;104(20):1790\u2013803. Chinese.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"8","key":"13834_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/jof9080812","volume":"9","author":"T Xue","year":"2023","unstructured":"Xue T, Kong X, Ma L. Trends in the epidemiology of pneumocystis pneumonia in immunocompromised patients without HIV infection. J Fungi (Basel). 2023;9(8):812.","journal-title":"J Fungi (Basel)"},{"key":"13834_CR19","doi-asserted-by":"publisher","first-page":"1155184","DOI":"10.3389\/fimmu.2023.1155184","volume":"14","author":"B Chen","year":"2023","unstructured":"Chen B, Qian G, Yang Z, et al. Virulence capacity of different aspergillus species from invasive pulmonary aspergillosis. Front Immunol. 2023;14:1155184.","journal-title":"Front Immunol"},{"issue":"11","key":"13834_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/apm.13316","volume":"131","author":"S Gaffney","year":"2023","unstructured":"Gaffney S, Kelly DM, Rameli PM, et al. Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices. APMIS. 2023;131(11):654\u201367.","journal-title":"APMIS"},{"key":"13834_CR21","doi-asserted-by":"publisher","first-page":"102901","DOI":"10.1016\/j.canep.2025.102901","volume":"98","author":"L Wang","year":"2025","unstructured":"Wang L, Jiang K, Qu M, et al. Epidemiology and risk factors of invasive pulmonary fungal disease in patients with lung cancer. Cancer Epidemiol. 2025;98:102901.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"13834_CR22","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/j.cllc.2020.10.001","volume":"22","author":"M Park","year":"2021","unstructured":"Park M, Ho DY, Wakelee HA, et al. Opportunistic invasive fungal infections mimicking progression of non- small cell lung cancer. Clin Lung Cancer Mar. 2021;22(2):e193\u2013200.","journal-title":"Clin Lung Cancer Mar"},{"issue":"2","key":"13834_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","volume":"7","author":"Q Wang","year":"2021","unstructured":"Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 Infection. JAMA Oncol Feb 1. 2021;7(2):220\u20137.","journal-title":"JAMA Oncol Feb 1"},{"issue":"9","key":"13834_CR24","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.21037\/apm-21-2364","volume":"10","author":"Y Chen","year":"2021","unstructured":"Chen Y, Wen F, Chen H, et al. Analysis of the pathogenic bacteria, drug resistance, and risk factors of postoperative infection in patients with non-small cell lung cancer. Ann Palliat Med Sep. 2021;10(9):10005\u201312.","journal-title":"Ann Palliat Med Sep"},{"issue":"1","key":"13834_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","volume":"13","author":"J Tanizaki","year":"2018","unstructured":"Tanizaki J, Haratani K, Hayashi H, et al. Nakagawa K. peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97\u2013105.","journal-title":"J Thorac Oncol"},{"key":"13834_CR26","doi-asserted-by":"crossref","unstructured":"Roohani AH, Fatima N, Shameem M, et al. Comparing the profile of respiratory fungal pathogens amongst immunocompetent and immunocompromised hosts, their susceptibility pattern and correlation of various opportunistic respiratory fungal infections and their progression in relation to the CD4 + T-cell counts. Indian J Med Microbiol. 2018 Jul-Sep;36(3):408\u201315.","DOI":"10.4103\/ijmm.IJMM_18_258"},{"issue":"1","key":"13834_CR27","doi-asserted-by":"publisher","first-page":"e0010122","DOI":"10.1128\/cmr.00101-22","volume":"37","author":"EG McDonald","year":"2024","unstructured":"McDonald EG, Afshar A, Assiri B, et al. Pneumocystis jirovecii pneumonia in people living with HIV: a review. Clin Microbiol Rev. 2024;37(1):e0010122.","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"13834_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/v9070194","volume":"9","author":"SN Pantry","year":"2017","unstructured":"Pantry SN, Medveczky PG. Latency, Integration, and Reactivation of Human Herpesvirus-6. Viruses. 2017;9(7):194. Published 2017 Jul 24.","journal-title":"Viruses"},{"issue":"1","key":"13834_CR29","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41598-019-38618-3","volume":"9","author":"EH Lee","year":"2019","unstructured":"Lee EH, Kim EY, Lee SH, et al. Risk factors and clinical characteristics of pneumocystis jirovecii pneumonia in lung cancer. Sci Rep. 2019;9(1):2094.","journal-title":"Sci Rep"},{"issue":"1","key":"13834_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","volume":"26","author":"JH Heinzerling","year":"2025","unstructured":"Heinzerling JH, Mileham KF, Robinson MM, et al. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol Jan. 2025;26(1):85\u201397.","journal-title":"Lancet Oncol Jan"},{"issue":"4","key":"13834_CR31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ijrobp.2024.01.217","volume":"119","author":"C Han","year":"2024","unstructured":"Han C, Qiu J, Bai L, et al. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2024;119(4):1179\u2013207.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"13834_CR32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/1759-7714.14867","volume":"14","author":"J Chen","year":"2023","unstructured":"Chen J, Ang KL, Wang Z, et al. Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small-cell lung cancer. Thorac Cancer. 2023;14(14):1260\u20137.","journal-title":"Thorac Cancer"},{"issue":"15","key":"13834_CR33","doi-asserted-by":"crossref","first-page":"15879","DOI":"10.1002\/cam4.6236","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Chen Y, Wang Y, et al. Risk factors for pulmonary infection in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study. Cancer Med. 2023;12(15):15879\u201391.","journal-title":"Cancer Med"},{"issue":"7","key":"13834_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895\u2013903.","journal-title":"Lancet Oncol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13834-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:17:44Z","timestamp":1787055464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13834-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13834"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13834-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethical standards of this study originate from international consensus represented by the Declaration of Helsinki, and are specifically implemented and supervised in China through a series of laws and regulations including the Measures for Ethical Review of Life Sciences and Medical Research Involving Human Subjects. The study was approved by the Institutional Review board at the Ethics Review Committee of the Fourth Hospital of Hebei Medical University (No. 2023KS206). The Ethics Review Committee of the Fourth Hospital of Hebei Medical University waived the requirement for written informed consent owing to the retrospective nature of the study; participants were also given the option to opt-out.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1518"}}